Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives

伦瓦提尼 医学 癌症研究 索拉非尼 肿瘤微环境 肿瘤科 肝细胞癌 癌症 药理学 内科学
作者
Yuhang Chen,Shengyuan Dai,Chien‐shan Cheng,Lianyu Chen
出处
期刊:Journal of Hematology & Oncology [Springer Nature]
卷期号:17 (1)
标识
DOI:10.1186/s13045-024-01647-1
摘要

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its primary mechanism of action involves inhibiting signal pathways such as vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), thereby reducing tumor cell proliferation and angiogenesis and affecting the tumor's immune microenvironment. In the treatment of liver cancer, although lenvatinib monotherapy has shown good clinical effect, the problem of drug resistance is becoming more and more serious. This resistance may be caused by a variety of factors, including genetic mutations, signaling pathway remodeling, and changes in the tumor microenvironment. In order to overcome drug resistance, the combination of lenvatinib and other therapeutic strategies has gradually become a research hotspot, and it is worth noting that the combination of lenvatinib and immune checkpoint inhibitors (ICIs) has shown a good application prospect. This combination not only enhances the anti-tumor immune response but also helps improve therapeutic efficacy. However, combination therapy also faces challenges regarding safety and tolerability. Therefore, studying the mechanisms of resistance and identifying relevant biomarkers is particularly important, as it aids in early diagnosis and personalized treatment. This article reviews the mechanisms of lenvatinib in treating liver cancer, the mechanisms and efficacy of its combination with immune checkpoint inhibitors, the causes of resistance, the exploration of biomarkers, and other novel combination therapy strategies for lenvatinib. We hope to provide insights into the use and research of lenvatinib in clinical and scientific settings, offering new strategies for the treatment of liver cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼应助11采纳,获得10
刚刚
昭谏发布了新的文献求助10
刚刚
1秒前
buno应助miles采纳,获得10
2秒前
3秒前
3秒前
小小宇宇发布了新的文献求助10
3秒前
3秒前
看不懂文献的进士完成签到,获得积分10
4秒前
7秒前
7秒前
8秒前
Yaon-Xu完成签到,获得积分10
9秒前
9秒前
10秒前
泥泥发布了新的文献求助200
12秒前
12秒前
12秒前
14秒前
15秒前
16秒前
17秒前
李健应助昭谏采纳,获得10
20秒前
22秒前
tuanheqi应助儒雅的涵柏采纳,获得50
22秒前
23秒前
游鱼完成签到,获得积分10
24秒前
24秒前
kjj完成签到,获得积分10
27秒前
爱小卖部的双黄蛋儿完成签到,获得积分10
29秒前
30秒前
31秒前
bxj完成签到 ,获得积分10
32秒前
科研通AI2S应助傻傻的沛容采纳,获得10
33秒前
34秒前
35秒前
一静齐眉发布了新的文献求助10
36秒前
37秒前
爱学习完成签到 ,获得积分10
37秒前
小小宇宇完成签到,获得积分10
38秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248513
求助须知:如何正确求助?哪些是违规求助? 2891903
关于积分的说明 8269128
捐赠科研通 2559920
什么是DOI,文献DOI怎么找? 1388768
科研通“疑难数据库(出版商)”最低求助积分说明 650897
邀请新用户注册赠送积分活动 627798